Genzyme Receives Company Award from European Organisation for Rare Diseases (EURORDIS)
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that it has received a Company Award from EURORDIS, the largest European patient organization in the field of rare diseases. The EURORDIS Company Award recognizes the outstanding accomplishments of companies dedicated to rare diseases. Genzyme was honored for pioneering the development and delivery of therapies for rare diseases. More>
Genzyme Receives European Label Expansion for Thyrogen
Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), today announced it has received European Commission approval of a product label expansion for the use of Thyrogen® (thyrotropin alfa) with a wider irradiation dose range for postoperative thyroid remnant ablation. More>
Genzyme Honours Innovation in Gaucher Disease Research through Its 2012 Gaucher Generation Program Awards
Genzyme, a Sanofi company, today announced the recipients of the 2012 Gaucher Generation Program awards, an annual program in its fifth year that awards scientists and clinicians engaged in innovative Gaucher disease research. More>
